Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenelzine
Drug ID BADD_D01750
Description Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Indications and Usage A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924]
Marketing Status Prescription
ATC Code N06AF03
DrugBank ID DB00780
KEGG ID D08349
MeSH ID D010624
PubChem ID 3675
TTD Drug ID D0P9AC
NDC Product Code Not Available
Synonyms Phenelzine | beta-Phenylethylhydrazine | beta Phenylethylhydrazine | Fenelzin | Phenethylhydrazine | 2-Phenethylhydrazine | 2 Phenethylhydrazine | Phenelzine Sulfate | Sulfate, Phenelzine | Nardelzine | Nardil
Chemical Information
Molecular Formula C8H12N2
CAS Registry Number 51-71-8
SMILES C1=CC=C(C=C1)CCNN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperpyrexia08.05.02.002--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Insomnia19.02.01.002; 17.15.03.0020.000290%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.0030.000290%
Mania19.16.02.002--
Metabolic acidosis14.01.01.003--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle twitching15.05.03.005--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Nystagmus06.05.02.006; 17.02.02.006--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000434%
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000290%Not Available
Paraesthesia17.02.06.005--
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000290%Not Available
Rash23.03.13.001--Not Available
Repetitive speech19.19.02.003; 17.02.08.012--Not Available
Schizophrenia19.03.04.001--Not Available
Seizure17.12.03.001--
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.000724%Not Available
Shock24.06.02.002--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages